

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		4104390	08-01-1978	Ferrand et al.	
		4147787	04-03-1979	Maffrand	
		4193997	03-18-1980	Boigegrain et al.	
		4321266	03-23-1982	Amselem et al.	
		4400384	08-23-1983	Amselem et al.	
		4500534	02-19-1985	Frehel et al.	
		4515951	05-07-1985	Boigegrain et al.	
		4529596	07-16-1985	Aubert et al.	
		4740510	04-26-1988	Badore et al.	
		5190938	03-02-1993	Badore et al.	
		5874581	02-23-1999	Ataka et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		CA 1147658	06-07-1983	Sanofi		
		EP 0 573 975	12-15-1993	Fuji Photo Film Col, Ltd.		
		EP 0 641 770	03-08-1995	Meiji Seika Kabushiki Kaisha		
		EP 1 350 511	09-10-2008	Daiichi Sankyo Company Limited		
		FR 2 596 392	10-02-1987	Sanofi		X
		FR 2 597 102	10-16-1987	Sanofi		X
		GB 1445524	08-11-1976	Centre D'Etudes Pour L'Industrie Pharmaceutique		
		GB 1501797	02-22-1978	PARCOR		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		GB 1561504	02-20-1980	Centre D'Etudes Pour L'Industrie Pharmaceutique		
		JP 6-271582	09-27-1994	Fuji Photo Film Co. Ltd.		X
		JP 8-291117	11-05-1996	Ube Ind. Ltd.		X
		JP 11-510818	09-21-1999	Sanofi Aventis		X
		WO 00/061537	10-19-2000	Nicox SA		
		WO 00/061541	10-19-2000	Nicox SA		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abou-Khalil et al., "Effects of Ticlopidine, A New Platelet Antiaggregating Agent, and Its Analogues on Mitochondrial Metabolism," Biochemical Pharmacology, 33(23), pp. 3893-3898, 1984	
		Abou-Khalil et al., "Mechanism of Interaction of Ticlopidine and Its Analogues With the Energy-Conserving Mechanism in Mitochondria," Biochemical Pharmacology, 35(11), pp. 1855-1859, 1986	
		Abou-Khalil et al., "Swelling of Mitochondria by the Platelet Antiaggregating Agent Ticlopidine," Biochemical Pharmacology, 35(11), pp. 1849-1853, 1986	
		Aono et al., "Effects of a New Antihypertensive Agent, SGB-1534, on Rat Platelet Aggregation," Japan J. Pharmacol., 42, pp. 493-500, 1986	
		Antman et al., "ACC/AHA Guidelines for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction," Journal of American College of Cardiology, 36(3), pp. 970-1062, 2000	
		Armstrong et al., "Reduction of Platelet Thromboxane A ₂ Production <i>ex vivo</i> and <i>in vivo</i> by Clopidogrel Therapy," International Society on Thrombosis and Haemostasis, pp. 613-615, 2009	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Asai et al., "CS-747 (Prasugrel, LY640315) Produces Potent And Sustained Platelet Inhibitory Effects In Dogs And Monkeys During Multiple Dosing That Are Enhanced By Co-administration Of Aspirin," J. Thromb. Haemost., 2005; 3 (Suppl. 1): P1111, Abstract and poster presentation	
		Asai et al., "Effects of CS-747, a novel P2Y ₁₂ receptor antagonist, on cerebral and peripheral arterial occlusive diseases in rats," J. Thromb. Haemostasis, 2003; 1 (suppl. 1): P2033	
		Asai et al., "Flow cytometric analysis of VASP phosphorylation in platelets treated with the active metabolite of prasugrel, a P2Y ₁₂ ADP receptor antagonist," J. Thromb. Haemost., 2007; 5 (Suppl. 2): P-S-652, Abstract and poster presentation	
		Asai et al., "The P2TAC receptor antagonistic actions of CS-747 and its metabolite, R-99224, in rats," J. Thromb. Haemost., 2001; Abstract 1915 and poster presentation	
		Baron et al., "Effects of the GP IIb/IIIa Antagonist SC-54701 of Fibrin Generation and Platelet-Fibrin Interactions in Thrombin Induced Clot Formation and Retraction," Thromb. Haemostasis, #1593, 73, No. 6, 1315, 1995	
		Bassand, "Combination Therapy or Triple-Antiplatelet Therapy?," the Heart.org, retrieved from http://www.theheart.org/documents/sitestructure/en/content/programs/1227579/1227579.ht... retrieved on July 22, 2011	
		Bassand, "Platelet Antiaggregation Treatment in the Aftermath of GUSTO IV, TARGET, TACTICS, and CURE Trials," Rev. Esp. Cardiol., 55(7), pp. 697-702, 2002	
		Bertrand et al., "Double-Blinded Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination with Aspirin compared with Ticlopidine in Combination with Aspirin after Coronary Stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS), Circulation 102, pp. 624-629, 2000	
		Bhatt, "Intensifying Platelet Inhibition-Navigating Between Scylla and Charybdis," N. Engl. J. Med., 357(20), pp. 2078-2081, November 15, 2007	
		Boysen, "Bleeding Complications in Secondary Stroke Prevention by Antiplatelet Therapy: A Benefit-Risk Analysis," Journal of Internal Medicine, 246, pp. 239-245, 1999	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Braunwald et al., "ACC/AHA Guidelines for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina), Circulation, 102, pp. 1193-1209, 2000	
		Buckland et al., "Prasugrel active metabolite yields complete inhibition of P2Y12-mediated amplification of platelet responses," UK Platelet Meeting 2006	
		Buckland et al., "Cangrelor inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor," Congress of the European Society of Cardiology 2009	
		Buckland et al., "Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites," J. Thromb. Haemost., 2009; 7 (suppl. 2): 589-590	
		CAP Today, "GRAVITAS Findings Part of Plavix Puzzle," College of American Pathologists, retrieved from http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtl_t_actionOverride=%2Fportlet%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtl_t&cntvwrPtl_t%7BactionForm.contentReference%7D=cap_today%2F1210%2F1210c_plavix.html&_state=maximized&_pageLabel=cntvwr , December 2010	
		Cattaneo et al., "ADP Receptors and Clinical Bleeding Disorders," Arterioscler Thromb Vasc Biol., 19, pp. 2281-2285, 1999	
		Currie et al., "Enhanced Circulatory Parameters of Human Platelets Cryopreserved with Second-Messenger Effectors: an <i>in vivo</i> Study of 16 Volunteer Platelet Donors," British Journal of Haematology, 105, pp. 826-831, 1999	
		Daiichi Sankyo Company Ltd, "Further Observations of the Proprietors in Relation to the Defence of EP 1 350 511 Against Oppositions, and in Preparation for Oral Proceedings, March 22, 2011," dated December 24, 2010	
		DeRay et al., "Clopidogrel Activities in Patients with Renal Function Impairment," Clinical Drug Investigation, 16(4), pp. 319-328, October 1, 1998, Abstract only	
		Dobesh, "Clopidogrel Versus Prasugrel: Times are Changing, but Not for Everyone," Pharmacotherapy, 29(12), pp. 1393-1396, 2009	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dovlatova et al., "Competition between reversible and irreversible P2Y12 antagonists and its influence on ADP-mediated platelet activation," J. Thromb. Haemost., 2007; 5 (Suppl. 2): P-S-340	
		The Epic Investigators, "Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty," The New England Journal of Medicine, 330(14) pp. 956-961, April 7, 1994	
		Ernest et al., "Population Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-Treated Patients with Stable Coronary Disease," J. Pharmacokinet Pharmacodyn, 35, pp. 593-618, 2008	
		European Patent No. 1350511 in the name of Daiichi Sankyo Company, Limited, Decision Revoking the European Patent, dated June 17, 2011	
		European Patent No. 1350511 in the name of Daiichi Sankyo Company, Limited, Provision of a copy of the minutes in accordance with Rule 124(4) EPC, dated June 17, 2011	
		Ferguson et al., "Antiplatelet Therapy in Clinical Practice," Martin Duntiz, Chapters 6 and 8-11, 2000	
		Frelinger III, et al., "The active metabolite of prasugrel (CS-747) inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Leukocyte-platelet and platelet-platelet aggregation and platelet surface P-selectin and activated GPIIb-IIIa," Circulation, 2005; 112(17), Supp. [2]: U449-U449. MA 1904.	
		Frelinger III, et al., "The active metabolite of prasugrel (CS-747) inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Modulation by other blood cells and calcium, but not by aspirin," J. Am. Coll. Cardiol., 2006; 47(4), Supp. [A]: 364A-364A	
		Giezen, "Optimizing Platelet Inhibition," European Heart Journal Supplements, 10(D), pp. D23-D29, 2008	
		Glasson et al., "Multiple Human Serum Binding of Two Thienopyridinic Derivatives, Ticlopidine and PCR 2362, and Their Distribution Between HAS, α_1 -Acid Glycoprotein and Lipoproteins," Biochemical Pharmacology, 31(5), pp. 831-835, 1982	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gorelick et al., "Therapeutic Benefit: Aspirin Revisited in Light of the Introduction of Clopidogrel," Stroke, 30, pp. 1716-1721, 1999	
		Grossmann et al., "Variable Extent of Clopidogrel Responsiveness in Patients After Coronary Stenting," Thromb. Haemost., 92, pp. 1201-1206, 2004	
		Gurbel et al., "Clopidogrel For Coronary Stenting. Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity," Circulation, 107, pp. 2908-2913, 2003	
		Gurbel et al., "Combination Antithrombotic Therapies," Circulation, 121, pp. 569-583, 2010	
		Hankey et al., "Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in Patients at High Risk of Vascular Disease?: A Systematic Review of the Evidence from Randomized Trials," Stroke, 31, pp. 1779-1784, 2000	
		Herbert et al., "Biochemical and Pharmacological Activities of SR 26831, A Potent and Selective Elastase Inhibitor," The Journal of Pharmacology and Experimental Therapeutics, 260(2), pp. 809-816, 1992	
		Hirsh et al., "Aspirin and Other Platelet-Active Drugs: The Relationship Among Dose, Effectiveness, and Side Effects," Chest, 108, pp. 247S-257S, 1995	
		Holmes et al., "ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDS "Boxed Warning," Circulation, 122, pp. 537-557, 2010	
		Huang et al., "Prevention of Arterial Thrombosis by Intravenously Administered Platelet P2T Receptor Antagonist AR-C69931 MX in a Canine Model," The Journal of Pharmacology and Experimental Therapeutics, 295(2), pp. 492-499, 2000	
		Iida et al., "A Potent and Specific Non-Peptide GPIIb/IIIa Antagonist," Thromb. Haemostasis, #1595, 73, No. 6, 1315, 1995	
		Jakubowski, J.A. et al., "A comparative study of the effects of prasugrel (CS-747, LY640315) and clopidogrel on platelet function in healthy subjects," Am. J. Cardiol., 2005; 96(7A): 149	
		Jakubowski, J.A. et al., "Comparison of a novel ELISA-based VASP whole blood (WB) assay with the flow cytometric (FC) technique," J. Thromb. Haemost., 2009; 7 (suppl. 2): 942	
		Jakubowski, J.A. et al., "Comparative Antiplatelet Effects Of The Active Metabolites Of CS-747 (Prasugrel, LY640315) And Clopidogrel," J. Thromb. Haemost., 2005; 3 (Suppl. 1): P2299	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Jakubowski, J.A. et al., "Platelet inhibitory effects of R-138727, the active metabolite of CS-747 a potent thienopyridyl P2Y-12 antagonist prodrug," FASEB J., 2002; 16, No. 4, Pt. 1, A203	
		Jakubowski et al., "Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile," Cardiovascular Drug Reviews, 25(4), pp. 357-374, 2007	
		Jakubowski et al., "Preclinical Efficacy of Prasugrel (CS-747, LY640315), a Novel and Potent Thienopyridine Oral P2Y12 ADP Receptor Antagonist," World Atherosclerosis Summit 2005	
		Jakubowski et al., "Stereoselective inhibition of human platelet aggregation by active metabolite of CS-747, a novel P2Y12 receptor antagonist," J. Thromb. Haemostasis, 2003; 1 (suppl. 1): P2056	
		Judge et al., "P2Y12 blockade by prasugrel active metabolite yields complete inhibition of P2Y12-mediated amplification of platelet responses," J. Thromb. Haemost., 2007; 5 (Suppl. 2): P-M-343	
		Judge et al., "Platelet function assays that assess response to P2Y12 antagonists vary widely in their sensitivities to low levels of P2Y12 receptor blockade," Eur. Heart J., 2008; 29 (Abstract Supplement): 835	
		Katano et al., "Tetrahydrothienopyridine Derivatives as Novel GPIIb/IIIa Antagonists," Bioorganic & Medicinal Chemistry Letters, 6(21), pp. 2601-2606, 1996	
		Kawano et al., "ME3277, a GPIIb/IIIa Antagonist Reduces Cerebral Infarction Without Enhancing Intracranial Hemorrhage in Photothrombotic Occlusion of Rabbit Middle Cerebral Artery," Journal of Cerebral Blood Flow and Metabolism, 20, pp. 988-997, 2000	
		Kawano et al., "Superiority of Platelet Integrin GPIIb-IIIa Receptor Antagonist over Aspirin in Preventing Cyclic Flow Reductions in the Guinea Pig Middle Cerebral Artery," European Journal of Pharmacology, 374, pp. 377-385, 1999	
		Kristensen, "Antithrombotic Treatment in Patients with Type 2 DM," Slide presentation, Copenhagen, Denmark 190710, WorldPharma July 17-23, 2010	
		Kurihara et al., "Potent inhibition of platelet aggregation by prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent, is associated with covalent binding of active metabolite to ADP receptor," Eur. Heart J., 2005; 26, No. Suppl. 1: 485, Abstract and poster presentation	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lazar et al., "Prasugrel for Acute Coronary Syndromes: Faster, More Potent, but Higher Bleeding Risk," Cleveland Clinic Journal of Medicine, 76(12), pp. 707-713, December 2009	
		Meng et al., "Effect of Acetylsalicylic Acid on Experimentally Induced Arterial Thrombosis in Rats," Naunyn-Schmiedeberg's Arch. Pharmacol., 301, pp. 115-119, 1977	
		Morikawa et al., "Sex Difference in the Effect of Aspirin on Rat Platelet Aggregation and Arachidonic Acid Metabolism," Japan J. Pharmacol., 37, pp. 317-323, 1985	
		Nagle, "Mixed Results Dampen Expectations for Eli Lilly's Prasugrel," retrieved from www.outsourcing-pharma.com/content/view/print/325169 , November 5, 2007	
		Nainggolan et al., "Ticagrelor Approval: US and Europe React," retrieved from www.theheart.org/article/1255711/print.do , July 21, 2011	
		Narita et al., "Antithrombotic Effect of TA-993, a Novel 1,5-Benzothiazepine Derivative, in Conscious Rats," Jpn. J. Pharmacol., 68, pp. 397-404, 1995	
		Niitsu et al., "CS-747 (Prasugrel, LY640315), A Novel Antiplatelet Agent, Inhibits Arterial Thrombosis Through Selective Blockade Of Platelet P2Y12 Receptors," J. Thromb. Haemost., 2005; 3 (Suppl. 1): P1708	
		Norgard, et al., "Comparison of Prasugrel and Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," Vascular Health and Risk Management, 5, pp. 873-882, 2009	
		O'Connor et al., "5-HT _{1B} And 5-HT _{2A} Receptor Antagonist Properties of SL 65.0472 <i>in vivo</i> ," Br. J. Pharmacol., 129, Proc., 58P, 2000	
		Ogawa et al., "Direct evidence for binding of the active metabolite of prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet drug, to human platelets," Eur. Heart J., 2006; 27, Suppl. 1, Abs. P4550	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 9 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ogawa et al., "Comparison of Antiplatelet and Antithrombotic Effects of Prasugrel and AZD6140," J. Thromb. Haemost., 2007; 5 (Suppl. 2): P-T-645	
		Ogawa et al., "Effective Inhibition Of Platelet Aggregation And Release Reaction With Lack Of Effect On Shape Change By CS-747 (Prasugrel, LY640315) And Its Active Metabolite," J. Thromb. Haemost., 2005; 3 (Suppl. 1): P2301	
		Ogawa et al., "Greater In Vivo Potency of Prasugrel (CS-747 LY640315) vs. Clopidogrel is Not Explained by Differential Activity of Active Metabolites," European Heart Journal, 26, suppl. 1, poster presentation, slide no. 61, Abstr, P2954, 2005	
		Okudaira et al., "A Study of the Intestinal Absorption of an Ester-Type Prodrug ME3229, in Rats: Active Efflux Transport as a Cause of Poor Bioavailability of the Active Drug," The Journal of Pharmacology and Experimental Therapeutics, 294(2), pp. 580-587, 2000	
		Okudaira et al., "Polarized Efflux of Mono- and Diacid Metabolites of ME3229, an Ester-Type Prodrug of a Glycoprotein IIb/IIIa Receptor Antagonist, in Rat Small Intestine," The Journal of Pharmacology and Experimental Therapeutics, 295(2), pp. 717-723, 2000	
		O'Riordan, "FDA Advisory Panel Votes Unanimously in Favor of Prasugrel," retrieved from http://www.theheart.org/article/939227.do , Heartwire, February 4, 2009	
		O'Riordan, "Prasugrel Bests Clopidogrel Without Bleeding Risk in STEMI Subgroup in TRITON-TIMI 38, Researchers Say," retrieved from http://www.theheart.org/article/944803/print.do , March 5, 2009	
		Otsuguro et al., "Antiplatelet, antithrombotic and antihemostatic effects of multiple administration of CS-747, a novel P2TAC receptor antagonist, in rats," J. Thromb. Haemost., 2001; Abst 1901	
		Poster Presentations, "Mechanisms of Platelet Activation I," The Authors. Journal Compilation, International Society on Thrombosis and Hemostasis, 7(2), 1-1204, poster presentations 317, 572, and 573, 2009	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rauch et al., "Mitogenic and Proinflammatory Actions of Thrombin-regulated P2Y12 ADP Receptor in Human Vascular Smooth Muscle Cells," Circulation, 2010; 23: 122: A15821	
		Rechner et al., "The sensitivity of a new cartridge for the PFA-100® system to inhibition of platelet function by the active metabolite of prasugrel (R-138727)," Gesellschaft fur Thrombose- und Hamostaseforschung 2008 Congress February (2008)	
		Satoh et al., "GP IIb-IIIa Antagonists Like Lamifiban (Ro 44-9883) That do not Induce Conformational Changes are Potent Inhibitors of Platelet Adhesion to Fibrinogen," Thromb.Haemostasis #1594, 73, No. 6, 1315, 1995	
		Serebruany et al., "Combination Antiplatelet Therapy with Aspirin and Clopidogrel: The Role of Antecedent and Concomitant Doses of Aspirin," Cardiology, 107, pp. 307-312, 2007	
		Serebruany et al., "Platelet Inhibition with Prasugrel (CS-747) Compared with Clopidogrel in Patients Undergoing Coronary Stenting: the Subset from the JUMBO Study," Postgrad Med J, 82, pp. 404-410, 2006, Abstract only	
		Shuldiner et al., "Association of Cytochrome P450 2C19 Genotype with the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy," JAMA, 302(8), pp. 849-858, August 26, 2009	
		Siegbahn et al., "Greater Platelet P2Y12 Inhibition by Prasugrel Compared to High Dose Clopidogrel Assessed by VASP Phosphorylation in Patients with Stable Coronary Artery Disease," J. Thromb. Haemost., 2007; 5 (Suppl. 2): O-T-031	
		Slugg et al., "Cirrhosis Does Not Affect the Pharmacokinetics and Pharmacodynamics of Clopidogrel," The Journal of Clinical Pharmacology, 40, pp. 396-401, 2000	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 11 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Smith et al., "ACC/AHA Guideline for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guideline)-Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to the Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty Endorsed by the Society for Cardiac Angiography and Interventions," Circulation, 103, pp. 3019-3041, 2001	
		Smith et al., "AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professional from the American Heart Association and the American College of Cardiology," J. Am. Coll. Cardiol., 38, pp. 1581-1583, 2001	
		Steinhubl et al., "Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention," Circulation, 103, pp. 2572-2578, 2001	
		The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group, "A Randomized Trial of Anticoagulants Versus Aspirin After Cerebral Ischemia of Presumed Arterial Origin," Ann. Neurol., 42, pp. 857-865, 1997	
		Sugidachi et al., "Active Metabolites Of CS-747 (Prasugrel, LY640315) And Clopidogrel Show Similar In Vitro P2Y12 Receptor Blockade But Greater In Vivo Potency Of CS-747," J. Thromb. Haemost., 2005; 3 (Suppl. 1): P1109	
		Sugidachi et al., "Effects of prasugrel (CS-747, LY640315) on platelet aggregation in P2Y12 receptor-deficient mice: Evidence for specific inhibition of P2Y12 receptors by prasugrel," Eur. Heart J., 2006; 27, Suppl. 1, Abs. P4557	
		Sugidachi et al., "Influence of Thienopyridines on Atherosclerotic Lesion Induced by Cholesterol Feeding in Two Animal Models," Circulation, 2008; 118(18), Suppl. 2: S478	
		Sugidachi et al., "The effects of major in vivo metabolites of prasugrel on human platelet aggregation," J. Thromb. Haemost., 2009; 7 (suppl. 2): 349	
		Szalony et al., "Extended Inhibition of Platelet Aggregation with the Orally Active Platelet Inhibitor SC-54684A," Circulation, 91, pp. 411-416, 1995	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Testa et al., "Current Concepts on Antiplatelet Therapy, Focus on the Novel Thienopyridine and Non-Thienopyridine Agents," Hindawi Publishing Corporation, Advances in Hematology, Article ID 595934, 2010	
		Tourmousoglou et al., "Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence," <u>Cardiovasc Hematol Agents Med Chem.</u> , 6(4), pp. 312-322, October 2008	
		"Thrombosis Prevention Trial: Randomised Trial of Low-Intensity Oral Anticoagulation with Warfarin and Low-Dose Aspirin in the Primary Prevention of Ischaemic Heart Disease in Men at Increased Risk. The Medical Research Council's General Practice Research Framework," Lancet, 351, pp. 233-241, January 24, 1998, Abstract only	
		Varenhorst et al., "Assessment of the platelet inhibitory effect of clopidogrel and prasugrel by the VerifyNow™ P2Y12 point-of-care device in comparison with LTA and VASP-phosphorylation in patients with stable coronary artery disease," Eur. Heart J., 2008; 29 (Abstract Supplement): 404	
		Venkatesan, "Why Prasugrel is heavily Indebted to Aspirin for its Glory?... The Curious Case of Human Platelet Business," Expressions in Cardiology, retrieved from http://drsvenkatesan.wordpress.com/2011/02/28/why-prasugrel-is-heavily-to-aspirin-for-its-glory-the-curious-case-of-human-platelet-business/ , February 28, 2011	
		Verstraete et al., Cardiovascular Thrombosis. Thrombocardiology and Thromboneurology," Second Edition, Lippincott-Raven Publishing, Chapters 9-11, 14 and 17, 1998	
		Vlachojannis et al., "Clopidogrel Resistance: Current Aspects and Future Directions," Hellenic J. Cardiol., 52, pp. 236-245, 2011	
		Wada, et al., "Correlation of Inhibition of Platelet Aggregation with Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes," The Journal of Clinical Pharmacology, 50(8), pp. 904-913, August 2010, Abstract only	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 13 of 13

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds Draper
Attorney Docket Number	17620-105003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Weksler, "Antiplatelet Agents in Stroke Prevention. Combination Therapy: Present and Future," Cerebrovasc. Dis., 10, suppl. 5, pp. 41-48, 2000, abstract only, retrieved from www.ncbi.nlm.nih.gov/pubmed/11096182	
		Younossi et al., "Effect of Combined Anticoagulation and Low-Dose Aspirin Treatment on Upper Gastrointestinal Bleeding," Digestive Diseases and Sciences, 42(1), pp. 79-82, January 1997	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.